Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: Described is an apparatus for inline urine analysis comprising a control unit and at least one image capture unit comprising an image sensor and an optical assembly. The apparatus is configured to be coupled with an indwelling urinary catheter or conduit leading from the catheter. Embodiments of the apparatus comprise a dispenser configured to dispense inert or reactive matter into the urine stream to aid in the analysis of properties of the urine and an illumination device configured to illuminate the urine stream. Also described is a system comprising at least one of these apparatuses and at least one image analyzer unit operatively connected to it. The image analyzer unit comprises a processor and software adapted to analyze the captured images to derive information therefrom relating to identification of properties of the urine and/or objects of interest in the urine stream. Embodiments of the system may comprise other peripheral devices.

Abstract: Described is an apparatus for inline urine analysis comprising a control unit and at least one image capture unit comprising an image sensor and an optical assembly. The apparatus is configured to be coupled with an indwelling urinary catheter or conduit leading from the catheter. Embodiments of the apparatus comprise a dispenser configured to dispense inert or reactive matter into the urine stream to aid in the analysis of properties of the urine and an illumination device configured to illuminate the urine stream. Also described is a system comprising at least one of these apparatuses and at least one image analyzer unit operatively connected to it. The image analyzer unit comprises a processor and software adapted to analyze the captured images to derive information therefrom relating to identification of properties of the urine and/or objects of interest in the urine stream. Embodiments of the system may comprise other peripheral devices.

Abstract: A method is provided for automatically creating data relating to an automation system, wherein a plurality of software agents is assigned to the automation system. The software agents are connected to the cloud via a gateway, wherein the cloud holds an agent configuration for each software agent. Data captured by at least some of the software agents and relate to at least one device, service, and/or data source of the automation system, which may be reached by the particular software agent, are received by the gateway. At least one software agent assigned to the automation system is configured by the gateway during processing of one or more agent configurations from the cloud and the captured data relating to at least one device, service, and/or data source may be reached by the particular software agent.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: A dosing system for transferring an aseptic fluid in dosages into a container, comprising a peristaltic pump configured such that the filling accuracy for fill volumes of the aseptic fluid <100 ?L is ±3 ?L.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: Systems and methods for improving safety of a multi-function portable personal communications device can include determining a first position of the personal communications device, after a predetermined time interval, determining a second position of the personal communications device, determining the distance between the first position and the second position, determining the time interval in which the personal communications device moved from the first position and the second position, calculating an average velocity of the personal communications device based on the first position, the second position and the time interval and, if the average velocity of the personal communication device exceeds a predetermined value, sending an alert or inhibiting a function of the personal communications device. Other systems and methods that improve safety are also disclosed.

Abstract: A peristaltic dosing device for providing dosages of a fluid at a volume of less than one milliliter comprises: a flexible tube, a counter pressure element, a plurality of actors and a drive. The flexible tube is essentially straightly arranged along the counter pressure element thereby forming a longitudinal axis. The actors arranged parallel to each other along the longitudinal axis. They are moveable by the drive in relation to the flexible tube. The flexible tube is compressible between the actors and the counter pressure element by moving the actors. Each of the actors is independently and linearly moveable by the drive along an actuation axis essentially perpendicular to the longitudinal axis of the flexible tube from a home position in which the flexible tube is least compressed to an end position in which the flexible tube is compressed and sealed between the respective actor and the counter pressure element.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: A data processing system is provided with a data verification system that is configured to perform a validation check upon receipt of a request from a field device to transfer data to the data processing system. The data verification system is also configured to verify a permission of the field device to exchange data and to validate the data integrity. A data landing zone is provided for temporary storage of the data in the event that a validation check fails, so that data errors may be corrected.

Abstract: A gateway device disposed within a managed network may be communicatively coupled to a computational instance of a remote network management platform. The gateway device may also be configured with a list of network addresses assigned to the managed network, and configured to: receive network traffic from computing devices on the managed network, compare source addresses of the network traffic to the network addresses in the list, discard a first unit of the network traffic that has source addresses that are specified in the list, and for a second unit of the network traffic with source addresses that are not specified by the list, (i) encrypt, as a whole, payloads of each packet of the second unit of the network traffic, and (ii) transmit the encrypted packets from the gateway device to the computational instance. Network addresses in the list may be provided by a gateway controller device.

Abstract: The invention pertains to a device for producing collections of sheet-like printed products from a supplied material strand, in which a switch feeds the product stream to a receiving cylinder via one of at least two collecting cylinders, as well as to a folding apparatus with such a collecting device.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: A method is provided for automatically creating data relating to an automation system, wherein a plurality of software agents is assigned to the automation system. The software agents are connected to the cloud via a gateway, wherein the cloud holds an agent configuration for each software agent. Data captured by at least some of the software agents and relate to at least one device, service, and/or data source of the automation system, which may be reached by the particular software agent, are received by the gateway. At least one software agent assigned to the automation system is configured by the gateway during processing of one or more agent configurations from the cloud and the captured data relating to at least one device, service, and/or data source may be reached by the particular software agent.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The invention is a catheter, which is formed from flexible material and has two basic configurations: An initial configuration, in which the catheter is supplied to the surgeon for insertion into the lumen of a patient, resembles a tension coil spring and a final configuration, which is an essentially linear configuration that is much longer and has a considerably smaller outer diameter than when it is in its initial configuration. The catheter is adapted to undergo a transformation from the initial configuration to the final configuration as it is pulled from its proximal end in order to withdraw it from the lumen of the patient.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.